Insights

Innovative Oncology Focus Lantern Pharma specializes in precision cancer treatments using AI-driven genomic data, creating opportunities to collaborate with biotech and pharmaceutical firms seeking advanced oncology solutions or licensing cutting-edge drug candidates.

Global Expansion Efforts The company's recent establishment of an AI center of excellence in India and expansion into Asia indicates a commitment to industrializing its platform globally, presenting potential partnerships in emerging markets and access to diverse patient data sets.

Regulatory Advancements The FDA clearance of IND application for STAR-001 highlights Lantern's momentum in clinical development, making it a strategic partner for organizations interested in co-developing or investing in early-stage oncology therapeutics.

Strategic Technology Leverage With proprietary AI platform RADR and integration of extensive data points, Lantern offers opportunities for tech collaborations or solutions providers to enhance drug discovery pipelines through tailored AI and data analytics services.

Financial Growth Potential With current revenues between 10M-25M and significant funding of 60M, Lantern presents an attractive prospect for investors and corporate partners aiming to capitalize on innovative cancer treatment pipelines and upcoming clinical milestones.

Lantern Pharma Inc. (Nasdaq: LTRN) Tech Stack

Lantern Pharma Inc. (Nasdaq: LTRN) uses 8 technology products and services including Google Workspace, Twemoji, Lightbox, and more. Explore Lantern Pharma Inc. (Nasdaq: LTRN)'s tech stack below.

  • Google Workspace
    Email
  • Twemoji
    Font Scripts
  • Lightbox
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • HubSpot
    Marketing Automation
  • PWA
    Miscellaneous
  • Quantcast
    System Analytics & Monitoring
  • Bootstrap
    UI Frameworks

Media & News

Lantern Pharma Inc. (Nasdaq: LTRN)'s Email Address Formats

Lantern Pharma Inc. (Nasdaq: LTRN) uses at least 1 format(s):
Lantern Pharma Inc. (Nasdaq: LTRN) Email FormatsExamplePercentage
First@lanternpharma.comJohn@lanternpharma.com
91%
FirstL@lanternpharma.comJohnD@lanternpharma.com
4%
Last@lanternpharma.comDoe@lanternpharma.com
3%
FLast@lanternpharma.comJDoe@lanternpharma.com
2%

Frequently Asked Questions

Where is Lantern Pharma Inc. (Nasdaq: LTRN)'s headquarters located?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s main headquarters is located at 1920 Mckinney Avenue Dallas, Texas 75201 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Lantern Pharma Inc. (Nasdaq: LTRN)'s official website and social media links?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s official website is lanternpharma.com and has social profiles on LinkedInCrunchbase.

What is Lantern Pharma Inc. (Nasdaq: LTRN)'s SIC code NAICS code?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Lantern Pharma Inc. (Nasdaq: LTRN) have currently?

Minus sign iconPlus sign icon
As of April 2026, Lantern Pharma Inc. (Nasdaq: LTRN) has approximately 26 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Financial Officer: D. M.Chief Scientific Officer: K. B.Vice President Clinical Development: R. E.. Explore Lantern Pharma Inc. (Nasdaq: LTRN)'s employee directory with LeadIQ.

What industry does Lantern Pharma Inc. (Nasdaq: LTRN) belong to?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN) operates in the Biotechnology Research industry.

What technology does Lantern Pharma Inc. (Nasdaq: LTRN) use?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s tech stack includes Google WorkspaceTwemojiLightboxModernizrHubSpotPWAQuantcastBootstrap.

What is Lantern Pharma Inc. (Nasdaq: LTRN)'s email format?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s email format typically follows the pattern of First@lanternpharma.com. Find more Lantern Pharma Inc. (Nasdaq: LTRN) email formats with LeadIQ.

How much funding has Lantern Pharma Inc. (Nasdaq: LTRN) raised to date?

Minus sign iconPlus sign icon
As of April 2026, Lantern Pharma Inc. (Nasdaq: LTRN) has raised $60M in funding. The last funding round occurred on Jan 14, 2021 for $60M.

When was Lantern Pharma Inc. (Nasdaq: LTRN) founded?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN) was founded in 2013.

Lantern Pharma Inc. (Nasdaq: LTRN)

Biotechnology ResearchTexas, United States11-50 Employees

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.

Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology.

Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

Section iconCompany Overview

Headquarters
1920 Mckinney Avenue Dallas, Texas 75201 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
11-50

Section iconFunding & Financials

  • $60M

    Lantern Pharma Inc. (Nasdaq: LTRN) has raised a total of $60M of funding over 7 rounds. Their latest funding round was raised on Jan 14, 2021 in the amount of $60M.

  • $1M$10M

    Lantern Pharma Inc. (Nasdaq: LTRN)'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $60M

    Lantern Pharma Inc. (Nasdaq: LTRN) has raised a total of $60M of funding over 7 rounds. Their latest funding round was raised on Jan 14, 2021 in the amount of $60M.

  • $1M$10M

    Lantern Pharma Inc. (Nasdaq: LTRN)'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.